GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BGLC · Jun 30, 2026

BioNexus Gene Lab Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001477932-26-005093General Corporate
Capex intensity50thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.33% · OPTIONAL · VALID

Operating cash generation5thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-554.77% · OPTIONAL · VALID

Revenue growth5thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

-96.63% · CORE · VALID

Inventory pressure95thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

857.31% · OPTIONAL · VALID

Gross margin95thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

17.05% · CORE · VALID

Operating margin5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-370.81% · CORE · VALID

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

17.95% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History29 statesSelf-history eligible
Sep 30, 20214/6 normalizedLevel 3Dec 31, 20214/6 normalizedLevel 3Mar 31, 20225/6 normalizedLevel 3Jun 30, 20225/6 normalizedLevel 3Sep 30, 20226/6 normalizedLevel 3Dec 31, 20226/6 normalizedLevel 3Mar 31, 20236/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedAmended as filedDec 31, 20236/6 normalizedLevel 3Mar 31, 20245/5 normalizedLevel 3Jun 30, 20245/5 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20246/8 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20256/9 normalizedLevel 3Mar 31, 20266/7 normalizedLevel 3Jun 30, 20266/7 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
1.42%
Current
0.33%
Delta
-1.09%
Cash Generation Increased
Previous
-646.49%
Current
-554.77%
Delta
91.72%
Growth Increased
Previous
-98.93%
Current
-96.63%
Delta
2.30%
Inventory Pressure Decreased
Previous
2920.73%
Current
857.31%
Delta
-2063.43%
Margin Increased
Previous
-3.46%
Current
17.05%
Delta
20.50%
Profitability Increased
Previous
-2366.21%
Current
-370.81%
Delta
1995.40%
R And D Intensity Decreased
Previous
63.42%
Current
17.95%
Delta
-45.47%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2025
Similarity
78%
Compared
6 dimensions
Coverage
100%
Growth 39.4 · Margin 20.0 · Profitability 20.0 · Capex Intensity 14.7 · Cash Generation 15.0 · Inventory Pressure 10.0
Sep 30, 2025
Similarity
63%
Compared
6 dimensions
Coverage
100%
Growth 40.0 · Margin 45.0 · Profitability 15.0 · Capex Intensity 7.9 · Cash Generation 5.0 · Inventory Pressure 65.0
Mar 31, 2026
Similarity
58%
Compared
6 dimensions
Coverage
100%
Growth 5.0 · Margin 95.0 · Profitability 5.0 · Capex Intensity 35.0 · Cash Generation 5.0 · Inventory Pressure 5.0
Mar 31, 2023
Similarity
57%
Compared
6 dimensions
Coverage
100%
Growth 15.0 · Margin 48.3 · Profitability 52.1 · Capex Intensity 25.0 · Cash Generation 48.3 · Inventory Pressure 55.0
Sep 30, 2023
Similarity
56%
Compared
6 dimensions
Coverage
100%
Growth 53.3 · Margin 59.7 · Profitability 26.3 · Capex Intensity 50.0 · Cash Generation 30.3 · Inventory Pressure 36.2
Research Graph

Related governed research

Analogous To · BGLC state analogue 3 →Compared To · Services-Medical Laboratories peers →Analogous To · BGLC state analogue 2 →Analogous To · BGLC state analogue 4 →Analogous To · BGLC state analogue 5 →Analogous To · BGLC state analogue 1 →Has State · BioNexus Gene Lab Corp →Transitioned To · BGLC Fundamental State →Transitioned To · BGLC CAPEX_INTENSITY_DECREASED →Transitioned To · BGLC CASH_GENERATION_INCREASED →Transitioned To · BGLC GROWTH_INCREASED →Transitioned To · BGLC INVENTORY_PRESSURE_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.